Company intelligence / Profile preview

GRO Biosciences

Cambridge, Massachusetts, United Statesgrobio.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Preclinical data show promising new modalities for reversing autoimmune disease without immunosuppression and eliminating anti-drug antibodies. Lead program in refractory gout moving toward clinical trials following $60M Series B financing in July,2024.[1][2]

Therapeutic areas: ImmunologyEndocrinologyRheumatology
Modalities: Protein therapeutics (incorporating non-standard amino acids)Recombinant proteins[1][4]
Industry: Biotech

Drug pipeline

2 assets

ProGly-Uricase

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Atlas Venture and Access Biotechnology are major investors/partners.Additional collaborative/partnered programs are referenced but not named specifically.[2]

Beyond the preview

Go deeper on GRO Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRO Biosciences.

Explore the full profile